Follow The Filings

AQST Aquestive Therapeutics Inc.

Health Care, filed as AQUESTIVE THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.5%
  • $2.7M
  • 1 add

In 2026 Q2 Nathan Fischel added to Aquestive Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 0.5% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel Add 0.51%

Who owns AQST

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 0.51%, was 0.35% Add +75.3% 645,915 $2.7M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by AQST's executives, directors and 10% owners in the last 12 months, from their Form 4s

All AQST insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $744K sold by 3 insiders under 10b5-1 plans
  1. Daniel Barber CEO
    Planned sale
    $106K 25,000 shares at $4.22 3.8% of stake
    Traded Oct 15 Filed Oct 16
    ↗
  2. Daniel Barber CEO
    Planned sale
    $120K 25,000 shares at $4.82 3.7% of stake
    Traded Sep 15 Filed Sep 16
    ↗
  3. Sherry Korczynski Chief Commercial Officer
    Planned sale
    $46K 8,750 shares at $5.22 3.6% of stake
    Traded Sep 9 Filed Sep 11
    ↗
  4. Daniel Barber CEO
    Planned sale
    $107K 25,000 shares at $4.29 4.1% of stake
    Traded Aug 17 Filed Aug 18
    ↗
  5. Daniel Barber CEO
    Planned sale
    $100K 25,000 shares at $4.01 3.9% of stake
    Traded Jul 15–16 Filed Jul 17
    ↗
  6. Julie Krop Director
    Planned sale
    $125K 25,000 shares at $5.02 100% of stake
    Traded Jun 23 Filed Jun 24
    ↗
  7. Daniel Barber CEO
    Planned sale
    $104K 25,000 shares at $4.16 3.8% of stake
    Traded Jun 15 Filed Jun 16
    ↗
  8. Daniel Barber CEO
    Planned sale
    $35K 8,257 shares at $4.29 1.2% of stake
    Traded May 15 Filed May 18
    ↗
  9. Cassie Jung COO
    Planned sale
    $474K 67,575 shares at $7.01 22% of stake
    Traded Oct 15, 2025 Filed Oct 17, 2025
    ↗
  10. Carl N Kraus Chief Medical Officer
    Planned sale
    $142K 20,272 shares at $7.00 6.7% of stake
    Traded Oct 15, 2025 Filed Oct 17, 2025
    ↗
  11. Peter E. Boyd See Remarks
    Planned sale
    $70K 10,000 shares at $7.00 3.6% of stake
    Traded Oct 15, 2025 Filed Oct 17, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 12 stock grants, 10 share withholdings for taxes, 7 sales to cover taxes, 5 option exercises, and 1 other transaction.

SEC filings

Recent issuer filings from EDGAR, 16 shown.

Filed Form Detail Links
8-K 5.03,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 1.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
424B3 Filing Doc
8-K 5.07,9.01 Filing Doc
8-K 1.01,1.02,2.02,2.03,3.02,7.01,9.01 Filing Doc
10-Q Filing Doc

Source: SEC EDGAR submissions, updated 9 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $50.58M $57.56M $44.54M
Gross profit * $29.75M $39.69M $25.99M
Gross margin * 58.8% 69.0% 58.3%
Net income -$7.87M -$44.14M -$83.78M
Net margin * -15.6% -76.7% -188.1%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $40.97M $88.22M $149.27M
Total non-current assets * $16.45M $13.2M $11.16M
Total assets $57.42M $101.42M $160.42M
Total current liabilities $18.31M $18.86M $47.61M
Total non-current liabilities * $145.6M $142.72M $146.48M
Total equity -$106.49M -$60.16M -$33.66M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$6.38M -$35.76M -$52.43M
Cash from investing -$995,000 -$159,000 -$562,000
Cash from financing $3.97M $83.59M $102.62M
Net change in cash -$3.4M $47.67M $49.62M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.